Evolus, Inc. (NASDAQ:EOLS) CFO Sells $65,069.88 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 6,494 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total value of $65,069.88. Following the completion of the transaction, the chief financial officer now owns 167,089 shares of the company’s stock, valued at $1,674,231.78. The trade was a 3.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Sandra Beaver also recently made the following trade(s):

• On Tuesday, March 18th, Sandra Beaver sold 8,996 shares of Evolus stock. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96.

Evolus Price Performance

EOLS stock opened at $9.99 on Thursday. The company has a market cap of $644.12 million, a PE ratio of -10.98 and a beta of 1.11. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a 50-day moving average price of $11.43 and a two-hundred day moving average price of $12.46. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on EOLS shares. Barclays lifted their price target on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $23.75.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently bought and sold shares of EOLS. Principal Financial Group Inc. increased its position in shares of Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock worth $368,000 after acquiring an additional 2,989 shares in the last quarter. Barclays PLC boosted its position in shares of Evolus by 12.9% in the fourth quarter. Barclays PLC now owns 105,786 shares of the company’s stock worth $1,167,000 after buying an additional 12,124 shares during the period. Frontier Capital Management Co. LLC acquired a new stake in shares of Evolus in the fourth quarter valued at about $2,648,000. Raymond James Financial Inc. purchased a new stake in shares of Evolus during the 4th quarter valued at about $575,000. Finally, JPMorgan Chase & Co. lifted its position in Evolus by 63.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock worth $2,753,000 after acquiring an additional 65,972 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.